title: Advanced Glycation End-Products and Their Receptors: Related Pathologies, Recent Therapeutic Strategies, and a Potential Model for Future Neurodegeneration Studies.
abstract: Advanced glycation end products (AGEs) are the result of a nonenzymatic reaction between sugars and proteins, lipids, or nucleic acids. AGEs are both consumed and endogenously formed; their accumulation is accelerated under hyperglycemic and oxidative stress conditions, and they are associated with the onset and complication of many diseases, such as cardiovascular diseases, diabetes, and Alzheimer's disease. AGEs exert their deleterious effects by either accumulating in the circulation and tissues or by receptor-mediated signal transduction. Several receptors bind AGEs: some are specific and contribute to clearance of AGEs, whereas others, like the RAGE receptor, are nonspecific, associated with inflammation and oxidative stress, and considered to be mediators of the aforementioned AGE-related diseases. Although several anti-AGE compounds have been studied, understanding the underlying mechanisms of RAGE and targeting it as a therapeutic strategy is becoming increasingly desirable. For achieving these goals efficiently and expeditiously, the C. elegans model has been suggested. This model is already used for studying several human diseases and, by expressing RAGE, could also be used to study RAGE-related pathways and pathologies to facilitate the development of novel therapeutic strategies.
authors.affiliation: Albert Einstein College of Medicine , Jack and Pearl Resnick Campus, 1300 Morris Park Avenue, Forchheimer Building, Room 209, Bronx, New York 10461, United States.
authors.forename: Adi
authors.initials: A
authors.lastname: Pinkas
authors.affiliation: Albert Einstein College of Medicine , Jack and Pearl Resnick Campus, 1300 Morris Park Avenue, Forchheimer Building, Room 209, Bronx, New York 10461, United States.
authors.forename: Michael
authors.initials: M
authors.lastname: Aschner
mesh_terms: D000818:Animals; D017173:Caenorhabditis elegans; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D006801:Humans; D008962:Models, Theoretical; D019636:Neurodegenerative Diseases / Q000378:metabolism* / Q000628:therapy; D000067759:Receptor for Advanced Glycation End Products / Q000378:metabolism*
chemical_list: D017127:Glycation End Products, Advanced; D000067759:Receptor for Advanced Glycation End Products